Introduction BRCA mutation testing allows index patients and their families to be provided with appropriate
INTRODUCTION
Individuals with a BRCA1/2 genetic mutation are at high risk of developing breast, ovarian, prostate, pancreatic, and other cancers during their lifetime. The risks are 40%-80% for breast cancer, 11%-40% for ovarian cancer, 1%-10% for male breast cancer, and up to 39% for prostate cancer 1, 2 . Identifying BRCA gene mutations is important so that cancer risk-reduction strategies can be provided both to the index patients and to their family members. However, because of the low prevalence of BRCA mutations in unselected breast cancer patients and the high cost of genetic testing, selecting appropriate subjects for testing is important. Many centres recommend genetic testing for women whose probability of harboring a BRCA gene mutation exceeds 10% 3 .
Recently, many studies have reported that, compared with other breast cancer subtypes, triple-negative breast cancer (tnbc)-that is, tumours negative for estrogen receptor (er), progesterone receptor (pr), and her2 (human epidermal growth factor receptor 2) on immunohistochemical (ihc) testing-is associated with a higher prevalence of BRCA1 mutations, especially in younger individuals [4] [5] [6] . The National Comprehensive Cancer Network guidelines include tnbc patients 60 years of age or less in the eligibility criteria for genetic testing 7 . However, the literature shows a wide range of variation in the prevalence of BRCA1 mutations in tnbc patients 4, 5, 8 . Several studies have reported that tnbc alone, without other risk factors, is not an appropriate independent criterion for genetic testing and have recommended that additional risk factors be evaluated [9] [10] [11] .
The ihc features of BRCA1-related breast cancer are similar to those of basal-like breast cancer, both usually displaying negativity for er, pr, and her2. Both are also characterized by overexpression of egfr (epidermal growth factor receptor) and basal cytokeratins, and by negativity for phosphate and tensin homologue (pten), which are considered to be predictors for BRCA1 mutation 8, [12] [13] [14] [15] .
We t herefore studied t he associat ion bet ween BRCA1/2 germline mutations and the ihc features of breast cancer to determine whether those features are independent predictors of BRCA1 mutations in Korean breast cancer patients.
METHODS
Our retrospective review considered 498 patients who were diagnosed with breast cancer and underwent BRCA1/2 genetic testing at Seoul National University Bundang Hospital between July 2003 and September 2012. Of those patients, 82 with ductal carcinoma in situ or microinvasive carcinoma were excluded from the analysis. Among the patients who had undergone BRCA genetic testing, 5 were also excluded because they were not the index patient in their family. Thus, the final analysis was based on 411 index patients with invasive breast cancer. Personal and family histories of breast or ovarian cancer and age at the time of diagnoses of breast cancer were obtained from medical records, and ihc findings about hormone receptor, her2, cytokeratin 5/6 (CK5/6), egfr, and p53 status were obtained from pathology reports. The study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB no. B-1212/184-301).
BRCA1/2 Analysis
All patients met at least one of the following testing criteria for BRCA mutational screening: breast cancer patient with a family history of breast or ovarian cancer, patient with early-onset breast cancer (age at diagnosis ≤ 40 years), bilateral breast cancer, multi-organ cancer, or male breast cancer. The median interval between breast cancer diagnosis and genetic testing was 15 days. BRCA1 and BRCA2 mutation analyses were performed by direct dna sequencing and multiplex ligation-dependent probe amplification.
IHC Analysis
Expression of standard biomarkers including er, pr, her2, and p53 was evaluated in formalin-fixed paraffin-embedded whole-tissue sections at the time of diagnosis. Cytokeratin 5/6 and egfr were evaluated later in the course of the present study. Formalin-fixed paraffin-embedded tissue sections (4 μ m) were dried, deparaffinized, and rehydrated using standard procedures. Staining for ihc was performed on a BenchMark XT autostainer (Ventana Medical Systems, Triple-negative breast cancer was defined as ihc negativity for er, pr, and her2. A cut-off value of less than 1% was used to determine er and pr negativity. Negative her2 status was accepted when ihc was scored as 0 or 1+ or when her2 was not detected by fluorescence in situ hybridization or silver in situ hybridization. Although samples from 3 patients whose her2 ihc score was 2+ were not tested by either fluorescence or silver in situ hybridization, all were er-positive, and the patients were therefore classified as non-tnbc. Positivity for egfr was accepted when ihc was scored 2+ or 3+. Positivity for CK5/6 was accepted if any invasive tumour cells showed cytoplasmic staining. Of the 93 tnbc patients, 68 with adequate formalin-fixed paraffin-embedded tissue blocks were examined for pten negativity using an anti-pten antibody (Y184: GeneTex, Irvine, CA, U.S.A.). Negativity for pten was accepted if pten staining was undetectable in tumour cells when compared with adjacent normal stromal cells.
Statistical Analysis
Prevalence of BRCA1/2 mutations was analyzed according to ihc features and was compared between the tnbc and non-tnbc groups on the basis of family history and age, using the Pearson chi-square test or Fisher exact test. Multivariate analysis by logistic regression was performed to estimate the value of selected variables to predict for BRCA1 or BRCA2 mutation. All statistical tests were performed using the IBM SPSS Statistics software application (version 21.0: IBM, Armonk, NY, U.S.A.). A p value less than 0.05 was considered to be statistically significant. Table i presents the characteristics of the study population. Of the 411 eligible patients, 50 (12.2%) had germline mutations in BRCA1 (6.1%) or BRCA2 (6.1%). In patients with a family history of breast cancer, the rate of BRCA1/2 mutation was 18.9%; in patients with a family history of ovarian cancer, the rate was 42.1%. The prevalence of BRCA1/2 mutation was 12.9% in early-onset patients and 19.6% in patients with bilateral breast cancer. However, when patients with a family history were excluded, the rate of BRCA1/2 mutation was 8.8% in early-onset patients and 10.0% in patients with bilateral breast cancer. There was no difference in mean age between patients with BRCA1/2 mutation and those with no mutation (40.7 years vs. 42.7 years, p = 0.281); but patients with BRCA1 mutation were younger than those with no mutation (34.8 years vs. 42.7 years, p < 0.001).
RESULTS

Characteristics of the Study Population
IHC Features of BRCA1 and BRCA2 Tumours
Table ii shows the frequency of BRCA mutations according to expression of CK5/6, egfr, p53, er, pr, her2, and tnbc. CK5/6 = cytokeratin 5/6; EGFR = epidermal growth factor receptor; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer.
On univariate analysis, statistically significant differences in BRCA1 mutation rates were observed depending on the expression of CK5/6, egfr, er, pr, and tnbc. No difference in the prevalence of BRCA2 mutations in the presence of a basal-like phenotype were observed (Table ii) . To identify independent predictors of BRCA1 mutation, we performed a multivariate analysis based on CK5/6, egfr, p53, and tnbc. On multivariate analysis, er, pr, and her2 were excluded because they interacted with tnbc, and only tnbc showed an association with BRCA1 mutations (Table iii) .
Comparison of BRCA Mutation Rates in TNBC and Non-TNBC Patients
BRCA1/2 mutations were significantly more prevalent in tnbc patients than in non-tnbc patients (26.9% vs. 7.9%, p < 0.001). In patients with a family history of breast or ovarian cancer, the prevalence of BRCA1/2 mutations was higher in those with tnbc than in those with non-tnbc regardless of age at diagnosis with breast cancer (40.0% vs. 11.9%, p < 0.001). In patients without a family history of breast or ovarian cancer, the overall prevalence of BRCA1/2 mutation was also higher in patients with tnbc than in those with non-tnbc (14.6% vs. 4.9%, p = 0.027). The prevalence of BRCA1 mutations was significantly higher in patients with tnbc than in those with non-tnbc (20.4% vs. 1.9%, p < 0.001), but the prevalence of BRCA2 mutations was not different in patients with tnbc and with non-tnbc (6.5% vs. 6.0%, p = 0.866). When patients were divided by age group (younger and older than 35 years), the BRCA1 mutation rate was higher in patients with tnbc than with non-tnbc in both age groups (Table iv) ; however, in the case of patients more than 35 years of age, the difference in prevalence between patients with tnbc and with non-tnbc was not statistically significant (13.3% vs. 1.2%, p = 0.063).
BRCA Mutation Rates According to PTEN Status in Patients with TNBC
Of the 68 patients tested for pten status, 37 (54.4%) were pten-negative, and 31 (45.6%) showed intact pten staining. The prevalence of BRCA1 and BRCA2 mutations did not differ by pten status (BRCA1: 18.9% vs. 25.8%, p = 0.495; BRCA2: 10.8% vs. 6.5%, p = 0.684). Similarly, the prevalence of BRCA1 or BRCA2 mutation did not differ between the groups when they were stratified by family history of breast or ovarian cancer ( Table v) .
DISCUSSION
In the present study, we evaluated the association between ihc features of breast cancer and BRCA mutation in a Korean population. We observed that, on univariate analysis, CK5/6, egfr, er, pr, and tnbc were associated with BRCA1 mutation. However, on multivariate analysis, only tnbc was predictive of BRCA1 mutation. No association between the basal-like phenotype and BRCA2 mutation was observed.
Since the recognition that BRCA1-related breast cancer is similar to basal-like breast cancer, several studies have suggested that features of basal-like breast cancer might help to identify carriers of BRCA1 mutations. Foulkes et al. 8 observed CK5/6 expression in 15 of 17 (88%) BRCA1-related breast cancers negative for er and her2, finding that expression of CK5/6 was associated with BRCA1 mutation. However, their study was limited to Ashkenazi Jewish women, and only breast cancer specimens negative for er and her2 underwent immunostaining for CK5/6. In our study, CK5/6 was associated with BRCA1 breast cancer on univariate analysis, but that association was not statistically significant on multivariate analysis. Lakhani and colleagues 12 compared 182 BRCA1 carriers with 109 control subjects and evaluated cytokeratins (CK14, CK5/6, CK17), osteonectin, and egfr expression as independent predictors of BRCA1 mutation. They found that er negativity and CK14 and CK5/6 expression were independent markers of BRCA1 mutation, suggesting that cytokeratin staining and er status, combined with a family history of breast or ovarian cancer, might more accurately predict the probability of carrying a BRCA1 mutation. Collins et al. 16 reported that the expression of basal cytokeratins and egfr could help to identify a subset of tnbc patients with a basal-like phenotype, but was not sufficient to identify women with tnbc who were likely to carry a germline BRCA1 mutation. Similarly, in our study, the basal-like phenotype was associated with BRCA1 mutation, but tnbc was the only significant predictive variable on multivariate analysis.
Several studies have reported that loss of pten expression is significantly associated with basal-like breast cancer and BRCA1-associated hereditary breast cancer 13, 15 . Phuah et al. 17 evaluated pten status for 26 tnbc patients and reported that the addition of 2 criteria (triple negativity and pten status) improved the sensitivity of the Manchester scoring method, suggesting that pten status could improve the identification of BRCA1 mutation carriers. We therefore evaluated pten status in 68 tnbc patients and compared the prevalence of BRCA1 mutations in the pten-intact and pten-negative groups. No difference between those groups was observed in our study. Whether loss of pten expression is associated with BRCA1-related breast cancer is still controversial, and further studies involving larger patient cohorts will be required to address this question.
Several studies have examined the prevalence of BRCA mutations in unselected tnbc patients [18] [19] [20] [21] , and their authors have suggested that tnbc patients should be considered for BRCA1 and BRCA2 genetic testing based on the evidence of high BRCA mutation prevalence in unselected tnbc patients. Muendlein et al. 18 assessed the prevalence of BRCA mutation in 100 unselected tnbc patients. They observed a 21% rate of BRCA mutation, and calculated that 38.1%-52.4% of BRCA1/2 mutation carriers would be missed under the current German and Austrian national guidelines for genetic testing, which do not include tnbc as a genetic testing criterion. Villarreal-Garza et al. 19 investigated 190 unselected Mexican women with tnbc at the age of 50 years or younger. They found that the prevalence of BRCA mutations was 30.3% in women who were diagnosed at the age of 40 years or younger and 18.3% in those diagnosed between the ages of 41 and 50 years. Sharma et al. 20 reported that the prevalence of BRCA mutations was 15.4% in 207 unselected tnbc patients in a study that incorporated stratification by significant family history and age at diagnosis. In their multivariate model, the probability of a BRCA mutation in a patient with significant family history and diagnosis at age 51 was 29.5%, which was much higher than the 5.3% for a patient with no significant family history and diagnosis at age 51. Couch et al. 21 analyzed 1824 tnbc patients unselected for family history of breast or ovarian cancer and found that 14.6% of the overall group carried deleterious germline mutations, with 11.2% having mutations in BRCA1 (8.5%) and BRCA2 (2.7%). They also analyzed the prevalence of BRCA mutation by family history of cancer and age. With no family history of cancer, the prevalence of BRCA1/2 mutation was 19.8%, 15.4%, 8.6%, 7.5%, and 1.4% in patients diagnosed at less than 35 years of age, 35-39 years of age, 40-49 years of age, 50-59 years of age, and more than 60 years of age respectively.
Although the prevalence of BRCA mutation was high for unselected tnbc patients in most studies, those studies included high-risk subjects with a significant family history and early-onset breast cancer, which could result in an overestimation of the BRCA mutation prevalence. The identification of BRCA mutations in tnbc patients can have a significant effect on treatment. Compared with patients having other breast cancer subtypes, those with tnbc often have a worse prognosis 22 , and no suitable targeted therapy has been developed for tnbc patients. However, the pathologic complete response rate reached 83% after cisplatin neoadjuvant chemotherapy in patients with BRCA1-related breast cancer 23 . Moreover, in carriers of BRCA1 or BRCA2 mutations, treatment with inhibitors of parp (poly adp ribose polymerase) has shown antitumour activity, leading to synthetic lethality in tumour cells 24 . Thus, the BRCA mutation status of patients with tnbc might be a predictor of response to those therapies.
Based on recent studies, it therefore seemed important to identify whether tnbc should be incorporated into Korean genetic testing criteria. In the present study, we found that tnbc is an independent predictor of BRCA1 mutation in patients at high risk of hereditary breast and ovarian cancer. Given a positive family history, the BRCA1 mutation rate was much higher in patients with tnbc than in those with non-tnbc (28.9% vs. 2.2%, p < 0.001). Even in tnbc patients more than 35 years of age with no family history, the BRCA1 mutation rate was more than 10%. Nevertheless, their mutation rate was not statistically significantly different from the rate for their non-tnbc counterparts (13.3% vs. 1.2%, p = 0.063). Our results suggest that tnbc might play an important role in stratifying a patient's risk of having a BRCA1 mutation, especially for patients with a family history of breast or ovarian cancer, or with early-onset breast cancer. Our study has several limitations. First, in this singleinstitution study, the patient population was relatively small. The results might have differed if the study population had been larger. Second, the study was somewhat focused on high-risk patients, representing a possible selection bias. Lastly, ihc results for some patients, such as those for CK5/6 and egfr, were missing.
CONCLUSIONS
In patients at high risk of hereditary breast and ovarian cancer, tnbc is an independent predictor for BRCA1 mutation. Other ihc features of basal-like breast cancer did not improve the predictive estimates for BRCA1 mutation risk. More research is required to identify the subset of women who are at a greater risk of carrying a BRCA1 mutation.
